Press Release

Biopharm Companies Applaud New National Strategy

PhRMA April 26, 2013

Washington, D.C. (June 17, 2011) — The Pharmaceutical Research and Manufacturers of America (PhRMA) Deputy Vice President Karl Uhlendorf noted recent developments in national health promotion and wellness with the following statement:

“Yesterday’s unveiling of the National Prevention and Health Promotion Strategy is an exceptional and worthwhile project whose cause America’s biopharmaceutical companies have long supported.  This strategy, developed by the National Prevention Council in coordination with outside experts and stakeholders, will focus on prevention and wellness, working to create healthy communities and eliminate health disparities through implementation under the Affordable Care Act.


PhRMA’s support of preventive medicine and wellness has always been a high priority among its members. Whether through the support of various other programs focused on medication adherence, preventive care, and wellness services or their collaboration with the Partnership to Fight Chronic Disease (PFCD), America’s pharmaceutical companies realize that preventive care is an essential step in saving lives.


The National Prevention Council deserves lauded thanks for their commitment to community wellness and prevention, as does the private sector stakeholders who have dedicated their expertise to understanding the grave national problem of chronic disease.  The implementation of today’s announced National Prevention and Health Promotion Strategy is a strong step in the right direction. On behalf of the millions of Americans affected by chronic disease, we look forward to its success.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.4 billion in 2010 in discovering and developing new medicines. Industry-wide research and investment reached a record $67.4 billion in 2010.

Find PhRMA Online:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on ensuring the flow of medicines during public health emergencies, visit